Nadia MJ Rupniak

Nadia MJ Rupniak is the Executive Vice President of Drug Development for Dignify Therapeutics. She was most recently Vice President of Research and Development at CoLucid Pharmaceuticals where she played a key role in the development of lasmiditan for migraine. Prior to that, she was a Distinguished Senior Investigator with Merck where she supported the development of numerous clinical candidates, including Emend® for emesis and Vioxx® for pain. Dr. Rupniak is an internationally recognized neuroscientist and drug developer, with experience in efficacy and safety pharmacology, toxicology, pharmacokinetics and metabolism, regulatory interactions, and the design of clinical studies.